A randomized, open-label study on the effect of nipocalimab on vaccine responses in healthy participants

A randomized, open-label study on the effect of nipocalimab on vaccine responses in healthy participants

Nipocalimab, a human immunoglobulin G (IgG) 1 monoclonal antibody, selectively binds the IgG-binding site on the neonatal Fc receptor (FcRn) and blocks IgG recycling, reducing IgG levels without impacting antigen presentation or T-/B-cell functions. In this phase 1, open-label study, we assessed the...

Full description

Saved in:
Bibliographic Details
Main Authors: Marta Cossu, Carolina Bobadilla Mendez, Amanda Jackson, Eugene Myshkin, Grace Liu, Edwin Lam, Ulf H. Beier, Kathleen Weisel, Brittney Scott, Jocelyn H. Leu, Sheng Gao, Dessislava Dimitrova
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
T cell–dependent
T cell–independent
vaccine
nipocalimab
immunoglobulin G
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2491269
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items